To Be Discontinued Injection Oncology
Decitabine Injection · 203 days since initial FDA posting
Brand: DECITABINE
FDA lists Decitabine Injection as To Be Discontinued (Ingenus Pharmaceuticals LLC).
No availability text on this FDA row.
Decitabine Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Decitabine Injection
- Manufacturer
- Ingenus Pharmaceuticals LLC
- Dosage Form
- Injection
- Presentation
- Decitabine, Injection, 50 mg (NDC 50742-430-01)
- Package NDC
- 50742-430-01
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Feb 20, 2026
- Last Updated
- Feb 20, 2026
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Decitabine Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.